Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.

BACKGROUND Effective treatment for primary biliary cirrhosis (PBC) resulting in slower progression and improved survival remains elusive. Cyclosporin A (CyA), which has been so effective in preventing human allograft rejection, has shown promise in small numbers of patients in early studies. METHODS Three hundred forty-nine patients with PBC were randomized to receive CyA, 3 mg.kg-1.day-1, or placebo in a multicenter study with follow-up for 6 years. The end point was death or liver transplantation. RESULTS Cox multivariate analysis showed time from entry to death or transplantation was significantly prolonged (by up to 50%) in the CyA-treated group. Liver-related mortality was also significantly lower. However, a univariate analysis of survival showed no statistical differences between the two groups. Biochemical liver indices deteriorated more slowly in the CyA-treated group, but serum creatinine concentration was elevated > 150 mumol/L in 9%, necessitating permanent discontinuation in half of these. A reduction in the dose of CyA was required in 11% because of hypertension. CONCLUSIONS CyA has some therapeutic potential in primary biliary cirrhosis, providing blood pressure and renal function are closely monitored.

[1]  A prospective trial of colchicine for primary biliary cirrhosis. , 1986 .

[2]  T. Strom,et al.  Cyclosporine: a new immunosuppressive agent for organ transplantation. , 1984, Annals of internal medicine.

[3]  J. Boyer,et al.  The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. , 1983, The New England journal of medicine.

[4]  P. Tugwell,et al.  Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis , 1990, The Lancet.

[5]  J. Hoofnagle,et al.  Primary Biliary Cirrhosis: A Model Autoimmune Disease , 1983 .

[6]  B. Kahan.  Drug therapy: cyclosporine , 1989 .

[7]  T. Starzl,et al.  The effect of hepatic stimulatory substance, isolated from regenerating hepatic cytosol, and 50,000 and 300,000 subfractions in enhancing survival in experimental acute hepatic failure in rats treated with D‐galactosamine , 1986, Hepatology.

[8]  B. von Graffenried,et al.  Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. , 1988, Transplantation proceedings.

[9]  P. Cerutti,et al.  Mechanism of cyclosporin A-induced immunosuppression. Cyclosporin A inhibits receptor-mediated and non-receptor-mediated lymphokine production as well as interleukin-2-induced proliferation in cloned T lymphocytes. , 1987, Cellular immunology.

[10]  E. Christensen.  Multivariate survival analysis using Cox's regression model , 1987, Hepatology.

[11]  J. Neuberger,et al.  Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. , 1985, Gastroenterology.

[12]  G. Bonsel,et al.  Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis , 1990, The Lancet.

[13]  S N Rasmussen,et al.  A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. , 1989, The New England journal of medicine.

[14]  P. Grambsch,et al.  Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis , 1988, Hepatology.

[15]  L. Hunt,et al.  A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. , 1987, Journal of hepatology.

[16]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[17]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[18]  G. Alexander,et al.  In vitro effect of cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis. , 1986, Gut.

[19]  D. Altman,et al.  Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.

[20]  F. Schaffner,et al.  Evaluation of colchicine therapy in primary biliary cirrhosis. , 1988, Gastroenterology.

[21]  G. Minuk,et al.  Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. , 1988, Gastroenterology.

[22]  M. Kaplan.  Medical Treatment of Primary Biliary Cirrhosis , 1989, Seminars in liver disease.

[23]  R Kay,et al.  A Markov model for analysing cancer markers and disease states in survival studies. , 1986, Biometrics.

[24]  N Tygstrup,et al.  Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. , 1985, Gut.

[25]  D. Cox.  Regression Models and Life-Tables , 1972 .

[26]  H. Thomas,et al.  EFFECTS OF CYCLOSPORIN A ON SUPPRESSOR AND INDUCER T LYMPHOCYTES IN PRIMARY BILIARY CIRRHOSIS , 1980, The Lancet.

[27]  E. Dickson,et al.  A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. , 1990, The New England journal of medicine.

[28]  Y. Chrétien,et al.  IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS? , 1987, The Lancet.

[29]  I. Mackay,et al.  Primary Biliary Cirrhosis: Current Knowledge, Perspectives, and Future Directions , 1989, Seminars in liver disease.